ATE196425T1 - Impfstoff gegen die lyme-krankheit - Google Patents

Impfstoff gegen die lyme-krankheit

Info

Publication number
ATE196425T1
ATE196425T1 AT91305971T AT91305971T ATE196425T1 AT E196425 T1 ATE196425 T1 AT E196425T1 AT 91305971 T AT91305971 T AT 91305971T AT 91305971 T AT91305971 T AT 91305971T AT E196425 T1 ATE196425 T1 AT E196425T1
Authority
AT
Austria
Prior art keywords
osp
burgdorferi
lyme disease
mammal
bacteria
Prior art date
Application number
AT91305971T
Other languages
English (en)
Inventor
William Marshall Acree
Bonnie Lee Wallace
Hsien-Jue Steve Chu
Lloyd George Chavez
David Scott Sandblom
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of ATE196425T1 publication Critical patent/ATE196425T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT91305971T 1990-07-06 1991-07-01 Impfstoff gegen die lyme-krankheit ATE196425T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54919090A 1990-07-06 1990-07-06

Publications (1)

Publication Number Publication Date
ATE196425T1 true ATE196425T1 (de) 2000-10-15

Family

ID=24192007

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91305971T ATE196425T1 (de) 1990-07-06 1991-07-01 Impfstoff gegen die lyme-krankheit

Country Status (11)

Country Link
EP (2) EP1016416A3 (de)
JP (1) JPH04297424A (de)
AT (1) ATE196425T1 (de)
AU (1) AU8014691A (de)
CA (1) CA2046025A1 (de)
DE (1) DE69132417T2 (de)
DK (1) DK0465204T3 (de)
ES (1) ES2149759T3 (de)
GR (1) GR3034460T3 (de)
IE (2) IE20010565A1 (de)
PT (1) PT98202B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6316005B1 (en) * 1994-04-11 2001-11-13 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
ES2270523T3 (es) * 1997-06-30 2007-04-01 The Administrators Of The Tulane Educational Fund Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
AU2001285049A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
HRP20050660A2 (en) * 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
ES2699812T3 (es) 2012-02-01 2019-02-12 Biopeptides Corp Péptidos de diagnóstico para la enfermedad de Lyme
US10006912B2 (en) 2013-12-06 2018-06-26 Biopeptides Llc Peptides for diagnosing lyme disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DE3942728C1 (en) * 1989-12-22 1991-05-23 Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
WO1991013630A1 (en) * 1990-03-05 1991-09-19 The United States Of America, Represented By The Secretary, United States Department Of Commerce ANTIGENIC PROTEINS OF $i(BORRELIA BURGDORFERI)
EP0536335A4 (en) * 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
ATE173693T1 (de) 1992-08-21 1998-12-15 Rolf Baechtiger Kettengetriebe mit veränderlichem übersetzungsverhältnis und zahnkette

Also Published As

Publication number Publication date
IE912303A1 (en) 1992-01-15
EP1016416A3 (de) 2002-10-23
JPH04297424A (ja) 1992-10-21
AU8014691A (en) 1992-01-09
EP0465204A2 (de) 1992-01-08
ES2149759T3 (es) 2000-11-16
DK0465204T3 (da) 2000-10-09
EP1016416A2 (de) 2000-07-05
PT98202B (pt) 1999-02-26
GR3034460T3 (en) 2000-12-29
EP0465204A3 (en) 1993-03-10
IE20010565A1 (en) 2002-07-10
CA2046025A1 (en) 1992-01-07
DE69132417D1 (de) 2000-10-26
PT98202A (pt) 1992-05-29
EP0465204B1 (de) 2000-09-20
DE69132417T2 (de) 2001-05-23

Similar Documents

Publication Publication Date Title
DE69132417D1 (de) Impfstoff gegen die Lyme-Krankheit
ES2141182T3 (es) Vacuna contra la enfermedad de lyme.
ES500567A0 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
ATE211767T1 (de) Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien
EA199700413A1 (ru) Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
BR8807376A (pt) Microorganismo atenuado,composicao farmaceutica e processo de produzir um microorganismo atenuado
NO176004C (no) Fremgangsmåte ved fremstilling av vaksine mot hunde-coronavirus
ATE200735T1 (de) Impfstoffkonjugat
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
ATE149569T1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
FI875015A0 (fi) Vaccin mot juverinflammation.
DE3467813D1 (en) Diagnostic antigen for swine pseudorabies disease virus carriers
ES8105930A1 (es) Procedimiento para la preparacion de vacunas de virus poli- valentes
ATE39055T1 (de) Verfahren zur immunisierung von schweinen gegen die aujeszky-krankheit.
ATE206138T1 (de) Helicobacter pylori antigen
Johns et al. Bovine vibriosis vaccination: immunity conferred by a single biotype
DE69119785D1 (de) Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
Geresi et al. The ontogenic development of antitoxin-producing capacity of humans and animals-- The immuno-modulation in immunization practice.
RU93008069A (ru) Способ иммунизации крупного рогатого скота
KR850700110A (ko) 백신 및 이의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee